Detalhe da pesquisa
1.
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
Blood
; 135(7): 463-471, 2020 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31841594
2.
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
N Engl J Med
; 378(25): 2386-2398, 2018 Jun 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-29860938
3.
Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study.
Am J Hematol
; 98(9): E233-E236, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37354069
4.
Final phase I substudy results of ivosidenib in patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome.
Blood Adv
; 2024 04 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38640348
5.
Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant.
Leukemia
; 35(11): 3278-3281, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33772143